FDA ‘high-risk’ foreign inspections: Post‒COVID-19 response to GMP challenges
Feature ArticlesChris T. Middendorf, MS • Lowell M. Zeta, JD
Biologics/ biosimilars/ vaccinesGlobalNorth AmericaPharmaceuticalsFeature ArticlesChris T. Middendorf, MS • Lowell M. Zeta, JDBiologics/ biosimilars/ vaccinesGlobalNorth AmericaPharmaceuticals